The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway
Authors
Keywords
SGLT2 inhibitor, NAFLD, Autophagy, IL-17/IL-23 axis, Inflammatory responses
Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 94, Issue -, Pages 107492
Publisher
Elsevier BV
Online
2021-02-26
DOI
10.1016/j.intimp.2021.107492
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Epidemiology of diabetes and diabetic complications in China
- (2018) Ronald C. W. Ma DIABETOLOGIA
- Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission
- (2018) Hao Zhou et al. Redox Biology
- Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study
- (2018) Paul Chi Ho Lee et al. Diabetes Therapy
- Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study
- (2018) Paul Chi Ho Lee et al. Diabetes Therapy
- Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
- (2018) Naveed Sattar et al. DIABETOLOGIA
- Liraglutide relieves myocardial damage by promoting autophagy via AMPK-mTOR signaling pathway in zucker diabetic fatty rat
- (2017) Ya Zhang et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- AMPK as a Therapeutic Target for Treating Metabolic Diseases
- (2017) Emily A. Day et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- The Macrophage Switch in Obesity Development
- (2016) Angela Castoldi et al. Frontiers in Immunology
- The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
- (2015) Volker Vallon Annual Review of Medicine
- IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
- (2015) Michele W L Teng et al. NATURE MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTORC1: Turning Off Is Just as Important as Turning On
- (2014) Don Benjamin et al. CELL
- Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD
- (2014) Á González-Rodríguez et al. Cell Death & Disease
- Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
- (2014) Hannele Yki-Järvinen Lancet Diabetes & Endocrinology
- Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes via a cAMP/PKA/Rho-Dependent Mechanism
- (2013) D. Wang et al. DIABETES
- IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice
- (2013) Isaac T.W. Harley et al. HEPATOLOGY
- Autophagy Regulates IL-23 Secretion and Innate T Cell Responses through Effects on IL-1 Secretion
- (2012) C. Peral de Castro et al. JOURNAL OF IMMUNOLOGY
- Antagonistic control of muscle cell size by AMPK and mTORC1
- (2011) Rémi Mounier et al. CELL CYCLE
- Autophagy as an innate immunity paradigm: expanding the scope and repertoire of pattern recognition receptors
- (2011) Vojo Deretic CURRENT OPINION IN IMMUNOLOGY
- Vγ4 γδ T Cell-Derived IL-17A Negatively Regulates NKT Cell Function in Con A-Induced Fulminant Hepatitis
- (2011) Na Zhao et al. JOURNAL OF IMMUNOLOGY
- Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings
- (2010) Elizabeth M. Brunt et al. HEPATOLOGY
- Cutting Edge: Spontaneous Development of IL-17–Producing γδ T Cells in the Thymus Occurs via a TGF-β1–Dependent Mechanism
- (2010) Jeong-su Do et al. JOURNAL OF IMMUNOLOGY
- Fatty liver: Role of inflammation and fatty acid nutrition
- (2010) Christopher D Byrne PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
- Interleukin-1 and IL-23 Induce Innate IL-17 Production from γδ T Cells, Amplifying Th17 Responses and Autoimmunity
- (2009) Caroline E. Sutton et al. IMMUNITY
- Autophagy regulates lipid metabolism
- (2009) Rajat Singh et al. NATURE
- Macrophage activation and polarization
- (2007) Fernando Oneissi Martinez Frontiers in Bioscience-Landmark
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started